Mroczko B, Szmitkowski M
Zakład Diagnostyki Biochemicznej AM w Białymstoku.
Pol Arch Med Wewn. 2001 Mar;105(3):203-9.
Lung cancer is biologically and clinically classified as non-small-cell lung cancer (NSCLC) or small cell lung cancer (SCLC). NSCLC is accounting for about 80% of lung cancers. Serum tumour markers may be helpful in diagnostic of this cancer and in monitoring of the tumour growth or tumour volume reduction. Recent studies have focused on a new family of markers--hematopoietic cytokines, defined also hematopoietic growth factors (HGFs). It has been shown that the actions of HGFs are not limited to hematopoietic cells but can also affect the proliferation of nonhematopoietic cells. Some clinical investigations have shown cell surface receptors for macrophage--colony stimulating factor (M-CSF) in cancer cells and autologous production of M-CSF in various human cell lines derived from cancer. The purpose of this investigation was to compare serum levels of M-CSF in NSCLC patients to a control group, to assess pre- and post treatment levels of M-CSF in relation to levels of commonly accepted tumour markers such as carcinoembryonic antigen (CEA) and cytokeratin fragment 19 (CYFRA 21-1), and to define the diagnostic sensitivity of G-CSF in NSCLC. In this study, the serum levels of tumour markers were measured in 34 patients with NSCLC and in 20 healthy subjects. Serum samples were drawn before surgery and 10, 30, 90, 180 and 270 days after surgery. M-CSF and CEA were assayed using ELISA system and CYFRA 21-1 was measured by radioimmunoassay (RIA). The serum level of M-CSF was significantly increased in cancer patients relative to the control group on the 10th day after operation. Concentrations of CYFRA 21-1 were decreased on the 10th day, CEA on the 30th day and M-CSF on the 90th day after surgery. The diagnostic sensitivity of M-CSF was 55%, CEA--62% and CYFRA 21-1-51%. The diagnostic sensitivity and the serum level of M-CSF were related to the stage of NSCLC. These results suggest that M-CSF may be useful in diagnostic and monitoring of NSCLC, but it needs further studies.
肺癌在生物学和临床上分为非小细胞肺癌（NSCLC）或小细胞肺癌（SCLC）。NSCLC约占肺癌的80%。血清肿瘤标志物可能有助于这种癌症的诊断以及监测肿瘤生长或肿瘤体积缩小情况。最近的研究聚焦于一类新的标志物——造血细胞因子，也被定义为造血生长因子（HGFs）。研究表明，HGFs的作用不仅限于造血细胞，还可影响非造血细胞的增殖。一些临床研究显示，癌细胞中有巨噬细胞集落刺激因子（M-CSF）的细胞表面受体，且源自癌症的各种人类细胞系能自身产生M-CSF。本研究的目的是比较NSCLC患者与对照组的血清M-CSF水平，评估M-CSF治疗前后的水平与癌胚抗原（CEA）和细胞角蛋白片段19（CYFRA 21-1）等常用肿瘤标志物水平的关系，并确定M-CSF在NSCLC中的诊断敏感性。在本研究中，检测了34例NSCLC患者和20名健康受试者的血清肿瘤标志物水平。在手术前以及术后10、30、90、180和270天采集血清样本。使用酶联免疫吸附测定（ELISA）系统检测M-CSF和CEA，通过放射免疫测定（RIA）检测CYFRA 21-1。术后第10天，癌症患者的血清M-CSF水平相对于对照组显著升高。术后第10天CYFRA 21-1浓度降低，第30天CEA降低，第90天M-CSF降低。M-CSF的诊断敏感性为55%，CEA为62%，CYFRA 21-1为51%。M-CSF的诊断敏感性和血清水平与NSCLC的分期有关。这些结果表明，M-CSF可能有助于NSCLC的诊断和监测，但还需要进一步研究。
